Table 2.
Approved peptide/protein-based therapies for neurological diseases.
| Name | Brand Name | Description | Condition/Disease | Route of Administration | Initial Approval Year |
|---|---|---|---|---|---|
| Cerliponase alfa | Brineura™ | Recombinant human tripeptidyl peptidase-1 | Neuronal ceroid lipofuscinosis type 2 disease | i.c.v. | 2017 |
| Glatiramer acetate | Copaxone® | Acetate salts of synthetic polypeptides of L-glutamic acid, L-alanine, L-tyrosine, and L-lysine | Relapsing forms of multiple sclerosis | s.c. | 1996 |
| Peginterferon beta-1a | Plegridy™ | Interferon beta-1a | Relapsing forms of multiple sclerosis | s.c. | 2014 |
| Natalizumab | TysabriI® | Humanized IgG4k monoclonal antibody | Relapsing forms of multiple sclerosis | i.v. | 2004 |
| Ocrelizumab | Ocrevus™ | Humanized anti-CD20 monoclonal antibody | Relapsing or primary progressive forms of multiple sclerosis | i.v. | 2017 |
| Ofatumumab | Kesimpta® | Anti-CD20 monoclonal antibody | Relapsing forms of multiple sclerosis | s.c. | 2020 |
| Eptinezumab | Vyepti™ | Humanized IgG1 antibody antagonizing CGRPR | Adult migraine | i.v. | 2020 |
| Erenumab | Aimovig™ | Human monoclonal antibody antagonizing CGRPR | Adult migraine | s.c. | 2018 |
| Fremanezumab | Ajovy™ | Humanized IgG2 antagonizing CGRPR | Adult migraine | s.c. | 2018 |
| Galcanezumab | Emgality™ | Humanized IgG4 antagonizing CGRPR | Adult migraine | s.c. | 2018 |
| Dinutuximab | Unituxin™ | GD2-binding monoclonal antibody | Pediatric patients with high-risk neuroblastoma | i.v. | 2015 |
CGRPR: antibody antagonizing calcitonin gene-related peptide receptor; i.c.v.: intracerebroventricular; s.c.: subcutaneous; i.v.: intravenous.